{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidakjhr4ivgq4kiobsexeeracoondp3f6oz2dbfjh46nv5gupgwii",
    "uri": "at://did:plc:k7h5fn3kdhjpj37pc6yhno2o/app.bsky.feed.post/3mkbah6su4b72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidheecxzcxxuvuhiaxv27zvbqt3bfqov3jfpsp2vn2j4rj4aokq3e"
    },
    "mimeType": "image/jpeg",
    "size": 63144
  },
  "path": "/article/rfk-jr-puts-psychedelics-on-fast-track-to-fda-review-and-approval/",
  "publishedAt": "2026-04-24T16:50:00.000Z",
  "site": "https://www.scientificamerican.com",
  "textContent": "The U.S. Food and Drug Administration is seeking to accelerate the review process for three companies that are studying psilocybin and an MDMA-like drug as treatments for depression and PTSD",
  "title": "RFK, Jr., puts psychedelics on fast track to FDA review and approval"
}